Peer-reviewedCC BY-NC-NDInternal Medicine
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression
Abstract
We herein report four patients who were unable to receive idecabtagene vicleucel (ide-cel) due to disease progression, despite undergoing leukapheresis within specification. The median age of the patients was 70 (range, 68-77) years old. Two patients had nonsecretory subtypes at the diagnosis. The median number of prior therapy lines was 4.5 (range, 4-6), and 3 patients were penta-refractory. All patients were refractory to the latest treatment. The median time from apheresis to ide-cel cancellation was 44.5 (range: 24-71) days. Our findings suggest that the nonsecretory subtype and penta-refractoriness may increase the risk of treatment discontinuation. Early ide-cel application and improved bridging therapy are warranted to enhance treatment completion after leukapheresis.
Related
- Discontinuing Surveillance of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms in Routine Practice: An External Application of the "Trivial" Criteria and the Resources it Would Release in Fourteen Health Systems.
- Impaired ex vivo T-cell expansion before leukapheresis is associated with out-of-specification tisagenlecleucel manufacturing in pediatric CD19+ALL
- Process Characterization and Determinants of CD3⁺ Cell Yield During Autologous Leukapheresis for CAR-T Cell Manufacturing: A Single-Centre Experience from Western India.
- Carotid atherosclerosis progression in patients with Parkinson’s disease: a prospective cohort study
- Fear of progression as a mediator between symptom burden and social alienation in lung cancer patients undergoing chemotherapy
BibTeX
@article{nakanishi2026analysis,
title = {{An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression}},
author = {Yoko Nakanishi and Masaki Ri and Shiori Mizutani and Nozomi Nishitarumizu and Yuki Furukawa and Yukiyasu Kato and Hirokazu Sasaki and Arisa Asano and Shiori Kinoshita and Tomotaka Suzuki and Tomoko Narita and Shohei Mizuno and Hiroyuki Miyashita and Takaomi Sanda and Takanori Nanri and Hirokazu Komatsu and Shinsuke Iida},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.6289-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6289-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression
AU - Yoko Nakanishi
AU - Masaki Ri
AU - Shiori Mizutani
AU - Nozomi Nishitarumizu
AU - Yuki Furukawa
AU - Yukiyasu Kato
AU - Hirokazu Sasaki
AU - Arisa Asano
AU - Shiori Kinoshita
AU - Tomotaka Suzuki
AU - Tomoko Narita
AU - Shohei Mizuno
AU - Hiroyuki Miyashita
AU - Takaomi Sanda
AU - Takanori Nanri
AU - Hirokazu Komatsu
AU - Shinsuke Iida
PY - 2026
DA - 2026/08/01
JO - Internal Medicine
DO - 10.2169/internalmedicine.6289-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/15/65_6289-25/_article
AB - We herein report four patients who were unable to receive idecabtagene vicleucel (ide-cel) due to disease progression, despite undergoing leukapheresis within specification. The median age of the patients was 70 (range, 68-77) years old. Two patients had nonsecretory subtypes at the diagnosis. The median number of prior therapy lines was 4.5 (range, 4-6), and 3 patients were penta-refractory. All patients were refractory to the latest treatment. The median time from apheresis to ide-cel cancellation was 44.5 (range: 24-71) days. Our findings suggest that the nonsecretory subtype and penta-refractoriness may increase the risk of treatment discontinuation. Early ide-cel application and improved bridging therapy are warranted to enhance treatment completion after leukapheresis.
SN - 1349-7235
SN - 0918-2918
ER -